At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback